The burgeoning landscape of emerging treatments for weight management has seen the rise of both retatrutide and tirzepatide, both dual approach agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://socialskates.com/story22084139/retatrutide-vs-tirzepatide-a-comparative-analysis